The current studies have extended our understanding of host resistance to EMT6 tumors using WT mice as tumor recipients, and, following surgical resection of tumor, by augmenting immunization with tumor cells (with CpG as adjuvant) with infusion of Fab anti-CD200R to block CD200:CD200R interactions. This evidence concerns the gene CD200R1 and neoplasm.